62222-38-2

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydroxy-2-phenyl-pyrimidine-4-carboxylic acid is used as a pharmaceutical intermediate for the development of new drugs. Its antioxidant and anti-inflammatory properties make it a promising candidate for the treatment of various diseases and conditions.
Used in Chemical Synthesis:
In the chemical industry, 5,6-dihydroxy-2-phenyl-pyrimidine-4-carboxylic acid is used as a building block for the synthesis of new compounds with potential therapeutic applications. Its unique structure allows for the creation of a variety of novel molecules with potential uses in medicine and other fields.
Additional research is needed to fully understand the potential uses and effects of 5,6-dihydroxy-2-phenyl-pyrimidine-4-carboxylic acid, but its current applications in the pharmaceutical and chemical industries highlight its potential as a versatile and valuable compound.

Upstream product

• 613-92-3 N-hydroxyl-benzamidine 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 749886-77-9 5-benzyloxy-6-oxo-2-phenyl-1,6-dihydro-pyrimidine-4-carboxylic acid tert-butyl ester 
• 613-92-3 N-hydroxybenzenecarboximidamide 
• 33229-29-7 C₁₃H₁₄N₂O₅ 
• 62222-36-0 methyl 5,6-dihydroxy-2-phenylpyrimidine-4-carboxylate 

Relevant academic research and scientific papers

Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively “Freeze” the pre-translocated complex during the polymerization catalytic cycle

Reverse transcriptase (RT) is responsible for replicating the HIV-1 genome and is a validated therapeutic target for the treatment of HIV infections. During each cycle of the RT-catalyzed DNA polymerization process, inorganic pyrophosphate is released as the by-product of nucleotide incorporation. Small molecules were identified that act as bioisosteres of pyrophosphate and can selectively freeze the catalytic cycle of HIV-1 RT at the pre-translocated stage of the DNA- or RNA-template-primer-enzyme complex.

RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural information

Pyrimidinol carboxylic acids were designed as inhibitors of HIV-1 RNase H function. These molecules can coordinate to two divalent metal ions in the RNase H active site. Inhibition of enzymatic activity was measured in a biochemical assay, but no antivira

HCV NS5b RNA-dependent RNA polymerase inhibitors: From α,γ- diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5- hydroxypyrimidinonecarboxylic acids. Design and synthesis

A new class of the HCV NS5b RNA-dependent RNA polymerase inhibitors, the dihyroxypyrimidinecarboxylic acid derivative, was designed from a diketoacid and meconic acid derivative discovered by screening. Mechanism of action and essential moieties required for activity were identified. The corresponding N-methylpyrimidinone was also prepared; both classes are novel, reversible, and selective inhibitors of the HCV NS5b polymerase with improved druglike characteristics.

Highly selective synthesis of 2-substituted-5-hydroxy-6-oxo-1,6- dihydropyrimidine-4-carboxylic acid derivatives using a novel protected dihydroxyfumarate

A high yielding (50-96%) route to 2-substituted-5-hydroxy-6-oxo-1,6- dihydropyrimidine-4-carboxylic acid derivatives has been developed using a rationally designed dihydroxyfumarate derivative. The fully unprotected pyrimidinone heterocycle was prepared i